COURSE ID 2885

Protein Formulation and Stability

AVAILABLE On-demand
12 Hours

On-Demand

Offering Price
$ 2150
Register Now

You will be redirected to our secure system.

Team Training

When you need on-site attention, we’re not just here to help, we’re there to help—right by your side.

Individual courses are remarkably effective. But sometimes when you have a specific need, it helps to have expert guidance right in the room with you and your team.

In that case, we’re happy to design a custom training for your entire team, whether online—or on-site.

Learn more

Remember – at checkout you can choose to take this course On-demand. We offer a 10% group discount when you register 2 of more attendees (up to 10). Contact us for larger groups.

Many of the new molecules being developed by pharmaceutical and diagnostic discovery groups are biologically based, including monoclonal antibodies, proteins, enzymes, etc. Unlike small molecules, these products are much more sensitive to the normal stresses that a product encounters both over the shelf life of the product and during the manufacturing process.

Both the formulation (stabilizers, surfactants, proper pH) and how the product is processed (reduced oxygen, lyophilization, spray drying, minimizing shear, and others) can have an impact on the success or failure of a product.

This 12-hour, accredited ON DEMAND training will begin with a brief overview of basic protein chemistry and degradation pathways followed by a short discussion on the different upstream techniques for growing and purifying the biomolecules of interest. The requirements for starting the development process will then be broken down followed by an in-depth discussion of the analytical tools necessary for development and finished product testing.

A discussion on the formulation development process for a biomolecule will be had, which will cover pre-formulation and formulation development strategies utilizing high throughput screening techniques. Process development will be discussed, including product compatibility with manufacturing equipment/product contact components, and lyophilization and spray drying as a means of long-term stabilization. A section will be dedicated to discussing the importance of container closure systems and potential interactions with the product, followed by a discussion on aggregates and particulate matter issues and concerns.

This course is intended for professionals in the Pharmaceutical, Biopharmaceutical, Diagnostic and Vaccine industries, especially those working in

departments such as:

– Chemistry

– Biochemistry

– Analytical

– Engineering

– Biology

Chemists, Biochemist, Biologists, Formulators and Engineers

working in product and process development and engineering will benefit greatly by attending this intensive training.

course instructor

J. Jeff Schwegman, Ph.D.
Founder and CEO, AB BioTechnologies

J. Jeff Schwegman, Ph.D.’s Courses
J. Jeff Schwegman, Ph.D. is the founder and chief executive officer of AB BioTechnologies where he manages the day to day operations of the company. Dr. Schwegman received his BS in Biochemistry from Indiana University in 1992 and began working at Cook Imaging in Bloomington Indiana, where he gained experience in analytical, formulation and process development. In 1999 he began graduate study in the Department of Industrial and Physical Pharmacy at Purdue University under the direction of Dr. Steve Nail, where his focus of research involved studying changes in the physical structure of biological molecules during lyophilization. Dr. Schwegman received his Ph.D. from Purdue University in 2003 and returned to Bloomington where he worked at Baxter Pharmaceutical Solutions as a Research Scientist in the Pharmaceutical Development group. He specializes in speaking and consulting in parenteral pre-formulation, formulation, analytical, and lyophilization of both small molecules and large biomolecules. In November 2005, he left Baxter and formed a life science company which specialized in developing new formulations and manufacturing processes for parenteral products. In February 2008, he formed AB BioTechnologies.